VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

DUBLIN--(BUSINESS WIRE)--The "CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025" report has been added to ResearchAndMarkets.com's offering. This report provides ...

GlobalData’s report assesses how CD70 CAR-T cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks ...

The second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood ...

which are a type of white blood cell. DLBCL typically starts as a quick growing mass in a lymph node, although, it can also start in other areas of the body such as the intestines, bones, brain, or ...

The FDA granted approval to Yescarta (axicabtagene ciloleucel) CAR T-cell therapy as a treatment for certain patients with large B-cell lymphoma that has returned. CAR T-cell therapy takes T-cells ...

GlobalData’s report assesses how CD19 and BCMA CAR T-Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks ...

Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...